Hsien-Hsien Lei reports that three companies, Neuromark, Psynomics, and SureGene, are now offering genetic tests for mental illness variants. Neuromark’s Mark-C test will test for markers GRIK2 and GRIA3, which are believed to increase the risk of suicidal thoughts in people on Celexa. Psynome tests for two mutations in the GRK3 gene associated with bipolar disorder. SureGene's AssureGene test will look at genes associated with patients at risk of developing psychosis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.